Review
Version 1
Preserved in Portico This version is not peer-reviewed
Mucin Glycans: A Target for Cancer Therapy
Version 1
: Received: 16 September 2023 / Approved: 18 September 2023 / Online: 18 September 2023 (09:39:45 CEST)
A peer-reviewed article of this Preprint also exists.
Sun, L.; Zhang, Y.; Li, W.; Zhang, J.; Zhang, Y. Mucin Glycans: A Target for Cancer Therapy. Molecules 2023, 28, 7033. Sun, L.; Zhang, Y.; Li, W.; Zhang, J.; Zhang, Y. Mucin Glycans: A Target for Cancer Therapy. Molecules 2023, 28, 7033.
Abstract
Mucin glycans are important component of the mucus barrier and vital defence against physical and chemical damage as well as pathogens. Abnormal expression of mucin glycans can lead to disease, especially cancer. Here, we first summarize the main types of glycosylation on mucins and the mechanisms by which abnormal mucin glycans occur. We next describe the role of ab-normal mucin glycans in cancer. Finally, we describe MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example.
Keywords
mucin; glycosylation; cancer; MUC1; targeted therapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment